Menu

Reimagine their treatment journey with RUKOBIA
MANAGING ADULTS WITH MULTIDRUG-RESISTANT HIV-1 IS CHALLENGING1

REIMAGINE THEIR TREATMENT JOURNEY WITH RUKOBIA

A first-in-class attachment inhibitor

A first-in-class attachment inhibitor that directly targets HIV-1 to protect CD4+ T-cells2

Durable virologic suppression

Durable virologic suppression demonstrated over 5 years3

Robust CD4+ T-cell recovery

Robust CD4+ T-cell recovery3

RUKOBIA — A BREAKTHROUGH FIRST-IN-CLASS TREATMENT WITH A NOVEL MOA2

RUKOBIA, as part of an optimised background regimen, is the only therapy developed for people living with MDR HIV-1 clinically proven to offer virologic suppression and CD4+ T-cell recovery over 5 years.2,3

RUKOBIA INCLUDED IN EACS 2022 GUIDELINES

When a 2-3 drugs active regimen cannot be constructed with NRTI, NNRTI, PI/b and INSTI, a drug with a new mechanism of action such as fostemsavir can be added to obtain such a 2-3 drugs active regimen.4

The many faces of people living with MDR HIV-1

See perspectives from people living with MDR HIV-1

View Now

First-in-class attachment inhibitor

Find out what makes RUKOBIA different from other ARV therapies5

Learn more

Durable 5-year efficacy

Explore the 5-year virologic suppression data for RUKOBIA for people living with MDR HIV-13

See the Data

Breaking news: 240-week BRIGHTE trial results

Dr. Mills shares an exciting announcement about the BRIGHTE 5-year data for RUKOBIA for people living with MDR HIV-13

Watch Video

ARV=antiretroviral; HIV-1=human immunodeficiency virus type-1; INSTI=integrase strand transfer inhibitor; MDR=multidrug-resistant; MOA=mechanism of action; NRTI=nucleoside reverse transcriptase inhibitor; NNRTI=nonnucleoside reverse transcriptase inhibitor; PI=protease inhibitor.

Adverse events should be reported. For the UK, reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

References:

  1. Ackerman P, Thompson M, Molina JM, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS. 2021;35(7):1061-1072.
  2. RUKOBIA Summary of Product Characteristics.
  3. Aberg J, Shepherd B, Wang M, et al. Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: Week 240 results of the Phase 3 BRIGHTE study. Poster EPB160. Poster presented at: 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada.
  4. EACS guidelines Version 11.1. October 2022.
  5. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.

PM-GBL-FST-WCNT-210010 | December 2022

Prescribing Information

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.